An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 7, 2007, Pages 2026-2030

  Han, Xiaojun ^a   Civiello, Rita ^a   Pin, Sokhom S ^a   Burris, Kevin ^a   Balanda, Lynn A ^a   Knipe, Jay ^a   Ren, Shelly ^a   Fiedler, Tracey ^a   Browman, Kaitlin E ^a   Macci, Robert ^a   Taber, Matthew T ^a   Zhang, Jie ^a   Dubowchik, Gene M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR 1 RECEPTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CYCLOPENTADIENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTIDEPRESSIVE AGENTS; AZA COMPOUNDS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; INDENES; KINETICS; MICE; MICE, INBRED BALB C; MODELS, CHEMICAL; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; WATER;

EID: 33847664301     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.008     Document Type: Article

References (25)

1. In: Robin L.N., and Regier D.A. (Eds). Psychiatric Disorders in America, The Epidemiological Catchment Area Study (1990), The Free Press, New York
2. Wong D.T., Bymaster F.P., and Engleman E.A. Life Sci. 57 (1995) 411
3. Contoreggi C., Ayala A., Grant S., Eckelman W., Webster E., and Rice K.C. Drugs Future 27 (2002) 1093
4. Páez-Pereda M., Arzt E., and Stalla G.K. Expert Opin. Ther. Patents 12 (2002) 1537
5. Dinan T.G. Hum. Psychopharmacol. Clin. Exp. 16 (2001) 89
6. O'Brien D., Skelton K.H., Owens M.J., and Nemeroff C.B. Hum. Psychopharmacol. Clin. Exp. 16 (2001) 81
7. Hauger R.L., Grigoriadis D.E., Dallman M.F., Plotsky P.M., Vale W.W., and Dautzenberg F.M. Pharmacol. Rev. 55 (2003) 21
8. Kehne J.H., Maynard G.D., De Lombaert S., and Krause J.E. Ann. Rep. Med. Chem. 38 (2003) 11
9. Grigoriadis D.E., Haddach M., Ling N., and Saunders J. Curr. Med. Chem.-Cent. Nerv. Syst. Agents 1 (2001) 63
10. Gilligan P.J., Robertson D.W., and Zaczek R. J. Med. Chem. 43 (2000) 1641
11. Keller P.A., Elfick L., Garner J., Morgan J., and McCluskey A. Bioorg. Med. Chem. 8 (2000) 1213
12. Han X., Michne J.A., Pin S.S., Burris K.D., Balanda L.A., Fung L.K., Fiedler T., Browman K.E., Taber M.T., Zhang J., and Dubowchik G. Bioorg. Med. Chem. Lett. 15 (2005) 3870
13. Han X., Pin S.S., Burris K., Fung L.K., Huang S., Taber M.T., Zhang J., and Dubowchik G. Bioorg. Med. Chem. Lett. 15 (2005) 4029
14. c log P was calculated using a licensed program from Tripos.
15. 2O (1:1). The plate was centrifuged for 30 min to separate compound from solution. The supernatant and standards were analyzed by HPLC to determine the solubility.
16. Kulagowski J.J., and Rees C.W. Synthesis (1980) 215
17. Redemann C.T., and Redemann C.E. Org. Syn. Coll. Vol. 3 (1955) 69
18. Spasov A.A., Larionov N.P., Sibiryakova T.B., Verovskii V.E., Anisimova V.A., Dudchenko G.P., Baldenkov G.N., and Men'shikov M.Y. Khim.-Farm. Zh. 32 (1998) 17
19. Anisimova V.A., Kuz'menko T.A., Spasov A.A., Bocharova I.A., and Orobinskaya T.A. Pharm. J. Chem. 33 (1999) 361
20. Dubowchik G.D., Michne J.A., and Zuev D. Bioorg. Med. Chem. Lett. 14 (2004) 3147
21. +.
22. 2, 0.5% BSA, 0.005% Triton X-100, 10 μg/mL aprotinin, and 10 μg/mL leupeptin). Assays were stopped by the addition of ice-cold buffer. Non-specific binding was defined with 10 μM o-CRF. These compounds are full antagonists of the CRF1R, as determined by their ability to inhibit CRF stimulated cAMP production in IMR-32 cells.
23. Dieterich K.D., and DeSouza E.B. Brain Res. 733 (1996) 113
24. Dubowchik G.M., Michne J.A., Zuev D., Schwartz W., Scola P.M., James C.A., Ruediger E.H., Pin S.S., Burris K., Balanda L.A., Gao Q., Wu D., Fung L., Fiedler T., Browman K.E., Taber M.T., and Zhang J. Bioorg. Med. Chem. Lett. 13 (2003) 3997
25. Grewal S.S., Shepherd J.K., Bill D.J., Fletcher A., and Dourish C.T. Psychopharmacology 133 (1997) 29